Semaglutide is studied as a long-acting agonist of the GLP-1 receptor. Its extended activity profile is part of what makes it a heavily studied single-receptor incretin agonist.
GLP-1 receptor signaling
Researchers examine how semaglutide engages the GLP-1 receptor and the downstream signaling involved in glucose-regulation and satiety pathways within controlled models. For the receptor family, see GLP-1, GIP & glucagon explained.
Comparative context
Semaglutide is frequently compared with dual and triple agonists — see semaglutide vs tirzepatide. Product page: Semaglutide research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.